Injectable Buprenorphine Shows Promise in Pregnancy
A study found that pregnant patients with opioid use disorder who received injectable buprenorphine had higher rates of abstinence from illegal opioids than those who received the sublingual formulation. The findings suggest that injectable buprenorphine may be a viable treatment option for pregnant women with opioid use disorder.
Researchers conducted a noninferiority randomized trial to compare the efficacy of injectable buprenorphine to sublingual buprenorphine in pregnant patients with opioid use disorder. The study included 140 participants across 12 outpatient perinatal treatment sites in the US. Patients received either weekly extended-release injections or daily sublingual tablets. The results showed that the injectable group had higher rates of abstinence from illicit opioids during pregnancy. Both groups had similar neonatal outcomes. The study suggests that injectable buprenorphine may be a useful treatment option for pregnant women with opioid use disorder.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.